This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Sanofi China.
Reference
Xu Y, et al. Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China. Clinical Drug Investigation : 25 Jan 2019. Available from: URL: http://doi.org/10.1007/s40261-019-00750-3
Rights and permissions
About this article
Cite this article
Teriflunomide more effective, less costly in relapsing MS in China. PharmacoEcon Outcomes News 821, 30 (2019). https://doi.org/10.1007/s40274-019-5647-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5647-6